Head-To-Head Comparison: SiBone (NASDAQ:SIBN) versus RxSight (NASDAQ:RXST)

SiBone (NASDAQ:SIBN) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Insider and Institutional Ownership

98.1% of SiBone shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 4.0% of SiBone shares are owned by insiders. Comparatively, 9.6% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

SiBone has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, RxSight has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for SiBone and RxSight, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	0	0	3	0	3.00
RxSight	2	9	1	0	1.92

SiBone presently has a consensus price target of $23.67, indicating a potential upside of 65.39%. RxSight has a consensus price target of $10.00, indicating a potential upside of 16.82%. Given SiBone’s stronger consensus rating and higher probable upside, research analysts plainly believe SiBone is more favorable than RxSight.

Profitability

This table compares SiBone and RxSight’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SiBone	-12.83%	-14.20%	-10.38%
RxSight	-21.93%	-11.56%	-10.31%

Earnings & Valuation

This table compares SiBone and RxSight”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$167.18 million	3.69	-$30.91 million	($0.56)	-25.55
RxSight	$147.06 million	2.38	-$27.45 million	($0.80)	-10.70

RxSight has lower revenue, but higher earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Summary

SiBone beats RxSight on 8 of the 14 factors compared between the two stocks.

About SiBone

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

About RxSight

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.